Ironwood Pharmaceuticals (NASDAQ:IRWD) Insider Ronald Silver Sells 127,890 Shares of Stock

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) insider Ronald Silver sold 127,890 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $4.52, for a total value of $578,062.80. Following the sale, the insider owned 313,680 shares of the company’s stock, valued at approximately $1,417,833.60. The trade was a 28.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Ironwood Pharmaceuticals Stock Performance

Shares of NASDAQ IRWD opened at $4.67 on Friday. The stock has a market capitalization of $761.49 million, a P/E ratio of 7.78 and a beta of 0.20. The stock’s fifty day moving average is $3.88 and its 200 day moving average is $3.95. Ironwood Pharmaceuticals, Inc. has a 52 week low of $0.67 and a 52 week high of $5.78.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). The firm had revenue of $106.51 million for the quarter, compared to the consensus estimate of $92.11 million. Ironwood Pharmaceuticals had a negative return on equity of 39.65% and a net margin of 28.26%. Equities research analysts forecast that Ironwood Pharmaceuticals, Inc. will post 1.04 earnings per share for the current year.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of IRWD. Range Financial Group LLC acquired a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter valued at about $1,436,000. Hillsdale Investment Management Inc. acquired a new position in shares of Ironwood Pharmaceuticals in the fourth quarter valued at approximately $3,897,000. GSA Capital Partners LLP boosted its position in Ironwood Pharmaceuticals by 84.7% during the 4th quarter. GSA Capital Partners LLP now owns 571,613 shares of the biotechnology company’s stock worth $1,926,000 after buying an additional 262,084 shares during the period. Persistent Asset Partners Ltd bought a new stake in Ironwood Pharmaceuticals during the 4th quarter worth approximately $613,000. Finally, WINTON GROUP Ltd acquired a new position in Ironwood Pharmaceuticals in the 4th quarter valued at approximately $554,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Zacks Research raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, July 1st. Weiss Ratings reissued a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a report on Monday, April 27th. Finally, Wall Street Zen raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Sunday, May 17th. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Ironwood Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $6.23.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.